

## REMARKS/ARGUMENT

### SUMMARY OF THE PRESENT AMENDMENT

In accordance with Rule 173(g), all of the amendments herein are relative to the issued patent -- not relative to the text that existed prior to the present amendment. Amendments other than those being presented for the first time herein were previously discussed in prior submissions. In the present amendment, claims 13 and 15 are amended to replace the word "aggregate" with the word "combined" as suggested by the Examiner during a telephone discussion with applicant's representative on August 12, 2008.

### SUMMARY OF INTERVIEW SUBSTANCE UNDER M.P.E.P. § 713.04

The undersigned had a series of telephone discussions with Examiner Haghighatian on August 12, 2008. The examiner stated that quality control personnel at the USPTO had requested that claims 13 and 15 be amended to delete the word "aggregate" in the phrase, "wherein the aggregate concentration of all bioavailability enhancing agents . . ." and replaced with the word "combined". Claims 13 and 15 have, therefore, been amended to replace "aggregate" with "combined" per the suggestion by the Patent Office.

### SUBMISSION OF REISSUE INVENTOR'S DECLARATION

Applicant encloses another Supplemental Declaration for Reissue Patent Application to Correct "Errors" Statement (37 C.F.R. 1.175).


### CONCLUSION

It is believed that the application is now in condition for allowance. Issuance of a notice of allowance is solicited.

Respectfully submitted,

THIS CORRESPONDENCE IS BEING  
SUBMITTED ELECTRONICALLY  
THROUGH THE PATENT AND  
TRADEMARK OFFICE EFS FILING  
SYSTEM ON August 13, 2008.

WOG:MAF:db

  
\_\_\_\_\_  
Mark A. Farley  
Registration No.: 33,170  
OSTROLENK, FABER, GERB & SOFFEN, LLP  
1180 Avenue of the Americas  
New York, New York 10036-8403  
Telephone: (212) 382-0700

# APPENDIX A

Claim Number (Status)	Nature of Change/Recitation	Supporting Text in Original Patent
1-12 (canceled)	n/a	n/a
13 (pending)	citric acid concentration; rewritten in independent form; “and/or” changed to Markush format	Table 1; Table 3
14 (pending)	claim dependency only	original claim 14
15 (pending)	citric acid concentration; rewritten into independent format; “and/or” changed to Markush format	original claim 15; Table 1; Table 3
16 (pending)	claim dependency only	original claim 16
17 (pending)	claim dependency only	original claim 17
18 (pending)	“about” removed before “10”	original claim 18
19 (pending)	typographical error “MRC”; no substantive change	original claim 19
20 (pending)	claim dependency only	original claim 20
21 (pending)	no change	original claim 21
22 (pending)	“about” removed; citric acid concentration	original claim 22; Tables 1 and 3
23 (pending)	“about” removed; citric acid concentration	original claim 23; Tables 1 and 3
24 (pending)	citric acid concentration	Claim 19
25 (pending)	pH range	col. 3, line 12
26 (pending)	pH range	col. 3, line 12
27 (pending)	aqueous saline	col. 3, line 2
28 (pending)	viscosity	col. 3, lines 19-20
29 (pending)	polyoxyethylene (20) sorbitan monooleate	original claim 16
30 (pending)	preservatives	original claim 17

Claim Number (Status)	Nature of Change/Recitation	Supporting Text in Original Patent
31 (pending)	aqueous saline; osmotic pressure	col. 3, line 2; col. 3, lines 16-18
32 (pending)	salmon calcitonin	examples 1, 2 and 3
33 (pending)	salmon calcitonin	examples 1, 2 and 3
34 (pending)	method of nasal administration	original claim 20; col. 3, lines 43-56
35 (pending)	method of nasal administration	original claim 20; col. 3, lines 43-56
36 (pending)	method of nasal administration	original claim 20; col. 3, lines 43-56
37 (pending)	method of nasal administration	original claim 20; col. 3, lines 43-56
38 (pending)	method of nasal administration	original claim 20; col. 3, lines 43-56
39 (pending)	method of nasal administration	original claim 20; col. 3, lines 43-56
40 (pending)	method of nasal administration	original claim 20; col. 3, lines 43-56
41 (pending)	pH range	col. 3, line 12
42 (pending)	pH range	col. 3, line 12
43 (pending)	aqueous saline; osmotic pressure	col. 3, line 2; col. 3, lines 16-18
44 (pending)	aqueous saline; osmotic pressure	col. 3, line 2; col. 3, lines 16-18
45 (pending)	preservatives	original claim 17